Emerging drugs for alopecia areata: JAK inhibitors

Matilde Iorizzo, Antonella Tosti

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


Introduction: Alopecia Areata is a common form of non-scarring hair loss that usually starts abruptly with a very high psychological impact. Due to the still not completely understood etiopathogenesis, at present there is no treatment that can induce a permanent remission and there is no drug approved for the treatment of this disorder. Areas covered: Leading existing treatment are briefly overviewed and then ongoing research on Janus Kinases Inhibitors is discussed, reviewing trials with oral and topical formulations so as new opportunities for other forms of alopecia, such as cicatricial alopecia. Expert opinion: JAK inhibitors represent a promise among alopecia treatments, but further studies are needed on long term safety. There is still no validated dosage for alopecia areata and the vehicles used for topical formulations seem not yet ideal in terms of skin penetration and reduced systemic absorption. Hopefully several studies are ongoing and we hope, in the near future, that JAK inhibitors will become part of the armamentarium to treat alopecia areata patients in terms of safety and costs.

Original languageEnglish (US)
Pages (from-to)77-81
Number of pages5
JournalExpert Opinion on Emerging Drugs
Issue number1
StatePublished - Jan 2 2018


  • Alopecia
  • alopecia areata
  • baricitinib
  • cicatricial alopecia
  • JAK inhibitors
  • ruxolitinib
  • tofacitinib
  • treatment

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Emerging drugs for alopecia areata: JAK inhibitors'. Together they form a unique fingerprint.

Cite this